Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ester Simeone

Showing results (1-10 of 93) with videos related to

Pageof 10
Sort By:
Melanoma Management|September 8, 2018
Anti-PD-1 and PD-L1 antibodies in metastatic melanomaEster Simeone, Paolo A Ascierto
Journal of Immunotoxicology|April 25, 2012
Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1Ester Simeone, Paolo A Ascierto
Melanoma Management|September 8, 2018
Vemurafenib plus cobimetinib in the treatment of mutated metastatic melanoma: the CoBRIM trialAntonio M Grimaldi, Ester Simeone, Paolo A Ascierto
Methods in Molecular Biology (Clifton, N.J.)|November 22, 2013
Marker utility for combination therapyEster Simeone, Antonio M Grimaldi, Paolo A Ascierto
Melanoma Management|September 8, 2018
Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanomaEster Simeone, Antonio M Grimaldi, Paolo A Ascierto
Current Opinion in Oncology|January 15, 2014
The role of MEK inhibitors in the treatment of metastatic melanomaAntonio M Grimaldi, Ester Simeone, Paolo A Ascierto
Recenti Progressi in Medicina|October 2, 2020
[Cutaneous squamous cell carcinoma: immunotherapy for locally advanced and metastatic disease]Luigi Scarpato, Ester Simeone, Claudia Trojaniello, et al.
Seminars in Oncology|November 16, 2010
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodiesPaolo A Ascierto, Ester Simeone, Mario Sznol, et al.
Cytokine & Growth Factor Reviews|December 17, 2014
The use of interferon in melanoma patients: a systematic reviewRossella Di Trolio, Ester Simeone, Giuseppe Di Lorenzo, et al.
Frontiers in Oncology|April 11, 2022
Quality of Life Predictors in Patients With Melanoma: A Machine Learning ApproachMonica Pinto, Nicola Marotta, Corrado Caracò, et al.
Pageof 10

Showing results (1-10 of 93) with videos related to

Sort By:
Pageof 10
Melanoma Management|September 8, 2018
Anti-PD-1 and PD-L1 antibodies in metastatic melanomaEster Simeone, Paolo A Ascierto
Journal of Immunotoxicology|April 25, 2012
Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1Ester Simeone, Paolo A Ascierto
Melanoma Management|September 8, 2018
Vemurafenib plus cobimetinib in the treatment of mutated metastatic melanoma: the CoBRIM trialAntonio M Grimaldi, Ester Simeone, Paolo A Ascierto
Methods in Molecular Biology (Clifton, N.J.)|November 22, 2013
Marker utility for combination therapyEster Simeone, Antonio M Grimaldi, Paolo A Ascierto
Melanoma Management|September 8, 2018
Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanomaEster Simeone, Antonio M Grimaldi, Paolo A Ascierto
Current Opinion in Oncology|January 15, 2014
The role of MEK inhibitors in the treatment of metastatic melanomaAntonio M Grimaldi, Ester Simeone, Paolo A Ascierto
Recenti Progressi in Medicina|October 2, 2020
[Cutaneous squamous cell carcinoma: immunotherapy for locally advanced and metastatic disease]Luigi Scarpato, Ester Simeone, Claudia Trojaniello, et al.
Seminars in Oncology|November 16, 2010
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodiesPaolo A Ascierto, Ester Simeone, Mario Sznol, et al.
Cytokine & Growth Factor Reviews|December 17, 2014
The use of interferon in melanoma patients: a systematic reviewRossella Di Trolio, Ester Simeone, Giuseppe Di Lorenzo, et al.
Frontiers in Oncology|April 11, 2022
Quality of Life Predictors in Patients With Melanoma: A Machine Learning ApproachMonica Pinto, Nicola Marotta, Corrado Caracò, et al.
Pageof 10